AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05371847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment for upper limb dysfunction
Description: clinical assessments and questionnaires
Study NCT05371847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retest assessment
Description: For the test-retest reliability testing, participants will be invited to have an additional appointment approximately 1 week after the main assessment.
Study NCT06770803 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Low Pressure Pneumoperitoneum
Description: The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
Study NCT06771154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebelimab Combined with Apatinib
Description: Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Apatinib, 250 mg, once daily (qd), orally (po). Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation.
Study NCT06771154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adebelimab
Description: Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation.
Study NCT06770244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive psychology-based intervention package
Description: The postpartum depression intervention program will be developed in accordance with the principles of positive psychology, incorporating online psychological interventions as the primary mode of delivery. Specifically, psychological courses and training based on positive psychology will be conducted in addition to the usual community-based primary health care. Interventions use formats that include online videos and supplemental materials. The aim of the intervention is to help pregnant and postpartum women understand mental health, enhance positive emotions, improve negative emotions, maintain interpersonal relationships, and explore life meaning. Additionally, one-on-one online consultations based on positive psychology will be offered to high-risk women.
Study NCT06770946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Application
Description: Amniotic Membrane Application:~This intervention involves the application of an amniotic membrane harvested intraoperatively from the fetal side of the placenta during cesarean delivery. The membrane is placed directly on the incision site before surgical closure to promote wound healing and reduce complications such as infection, dehiscence, and scarring. The membrane is removed 24 hours postoperatively, and standard wound care is continued thereafter.
Study NCT06110832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Meditation and Yoga program
Description: In the mindfulness-based meditation and yoga program, mindfulness-based formal and informal interventions are conducted for 8 weeks.
Study NCT06401161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3T Pu'er tea
Description: Two types of Pu-erh tea with different levels of theabrownin content.
Study NCT06401161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3T Pu'er tea
Description: Two types of Pu-erh tea with different levels of theabrownin content.
Study NCT06541223 — intervention group
Intervention type: OTHER
Intervention: Standard informed consent procedure
Description: Face-to-face informed consent procedure supported by informational brochure
Study NCT06541223 — intervention group
Intervention type: OTHER
Intervention: Multimedia video
Description: Multimedia presentation on implant-based reconstruction
Study NCT05307315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to music
Description: The experimental group will listen to Turkish instrumental music with headphones for 30 minutes.
Study NCT06384885 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Lung ultrasound
Study NCT05179317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion
Study NCT03315832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
Study NCT03315832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
Study NCT06267833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.
Study NCT06267833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.
Study NCT06067880 — intervention group
Intervention type: OTHER
Intervention: Cancer-related Unilateral
Description: This group included patients who have used only contraction type LVs.
Study NCT06067880 — intervention group
Intervention type: OTHER
Intervention: Normal + Ectasis LVs
Description: This group included patients who had only non- contraction type LVs.
Study NCT04370327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Exercise (PF)
Description: Patients will exercise until the onset on claudication (1 on the rating scale)
Study NCT04370327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Claudication Pain Exercise (MOD-P)
Description: Patients will exercise until they experience moderate claudication pain (2 on the rating scale)
Study NCT04370327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maximal Claudication Pain Exercise (MAX-P)
Description: Patients will exercise until they experience maximal claudication pain (4 on the rating scale)
Study NCT05625776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain delivery with capsaicin and heat
Description: Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful
Study NCT05625776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: distractor delivery with sensory TENS
Description: Distractor stimulus delivered (sensory TENS electrical stimulation) that is short-term and attention-demanding but not painful
Study NCT05201755 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: Application of PEEP (positive end-expiratory pressure) through a CPAP Helmet with a set PEEP of 10 cmH2O. It is a very well tolerated and noninvasive device commonly used for ventilatory support.
Study NCT02926521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-octyl cyanoacrylate
Description: Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
Study NCT02926521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gum Mastic
Description: Addition of gum mastic liquid adhesive to nerve catheter dressing
Study NCT05630391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Fidelity Simulation Manikin
Description: A high-fidelity simulator was developed to teach skills in nursing education, and it is sized to represent an adult male patient. The mannequin can be controlled using a computer program, it can breathe, and its vital signs can be monitored using a bedside monitor.
Study NCT05630391 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Training for 26 nursing students who constituted the control group performed personnel protective equipment (PPE) wearing-removal practice
Study NCT04510428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocular Surface Immune Globulin (OSIG)
Description: Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks
Study NCT04510428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
Study NCT00960726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV-002
Description: 60 mg delivered daily subcutaneously for up to 12 months.
Study NCT06390072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Hypnosis
Description: Participants listened to an 8-minute audio-guided self-hypnosis related to improving their physical performance
Study NCT06390072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Hypnosis
Description: Participants listened to an 8-minute audio-guided self-hypnosis related to improving their physical performance
Study NCT06390072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Education
Description: Participants listened to an 8-minute video on ankle sprain diagnosis, prognosis, and treatment
Study NCT06390072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ankle Education
Description: Participants listened to an 8-minute video on ankle sprain diagnosis, prognosis, and treatment
Study NCT05098262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/500mg
Description: single dose administration (one tablet once a day)
Study NCT06444672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Rehabilitation program
Description: Home-based rehabilitation program The investigators used the ASIA scale to evaluate the sensory function and voluntary movement7. The HBRP included whole-body training with various exercises for stretching, strength, endurance, and aerobic fitness. The treatment sessions were performed three times per week and had a 50-120-minute duration. The exercises were modified based on individual progress and included the use of a rubber ball for balance and strength as well as trunk flexibility, static balance, stability, and standing exercises. Participants who could stand with assistive devices (such as knee-ankle-foot orthoses, KAFO) performed walking exercises.
Study NCT06444672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee-Ankle-Foot-Orthosis
Description: It is used to assist the participant in holding his /her body weight on the lower limb through standing and walking
Study NCT05561790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCBT-I
Description: Automated digital administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy modules via mobile or web application, lasting approximately six weeks.
Study NCT03622697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Phone Application
Description: Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for at least 4 weeks with periodic survey assessments using validated psychometric tools.
Study NCT05098262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/500mg
Description: single dose administration (one tablet once a day)
Study NCT05942287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
Study NCT05219955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Action Plan Execution
Description: Each day, participants are asked to track if they do the morning activity plan.
Study NCT05219955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Strategy-based Session with Therapist
Description: Participants will meet weekly with a trained therapist to discuss their prescribed activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one. Each session lasts about 30-45 minutes.
Study NCT05219955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-based Session with Therapist
Description: Participants will meet weekly with trained a therapist to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials
Study NCT05219955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance sleep-wake time
Description: Some participants will be asked to adjust their sleep schedule to accommodate morning activity engagement by introducing or altering mechanisms known promote early rising (i.e., light exposure, reward and processes, etc.)
Study NCT06500416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis Symfony OptiBlue/ Tecnis Symfony OptiBlue toric IOL
Description: Tecnis Symfony lens (DXR00V/ZXR00V) has the OptiBlue violet light filter (VLF), which blocks short-wavelength light. Violet light filtration reduces light scatter, improving contrast and reducing nighttime visual disturbances such as halo, glare, and starbursts.
Study NCT04851600 — intervention group
Intervention type: DEVICE
Intervention: prosthesis
Description: Casting and delivery of a cosmetic upper limb prosthesis at 3-4 months old of age.
Study NCT05988151 — intervention group
Intervention type: OTHER
Intervention: New surgical approach
Description: Patients were included in the study after obtaining informed consent for the new surgical approach inspired by the Fibonacci ratio.
Study NCT05358847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
Study NCT06086847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive resistant exercises
Description: Group A (Experimental Group):~• Warm up Exercise + stretching Exercise (upper and lower extremity) + progressive resistance exercises Warm up Exercise (for 5 min) Stretching (upper and lower extremity)~3. Progressive Resistance exercises:~1. Leg press :( dual leg press): Leg press target the~   Quadriceps or quads .but they also work your Hamstrings.~2. Leg curls (dual leg curls):~Leg curls Target the hamstrings and Calf muscles Leg Extension~The Muscles worked:~1. Rectus femoris~2. Vastus lateralis~3. Vastus medialis~4. Vastus intermedius~4. Arm lat pull (dual arm lat pull):~Back extension (lumber extension):
Study NCT06086847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: progressive resistant exercises
Description: Group A (Experimental Group):~• Warm up Exercise + stretching Exercise (upper and lower extremity) + progressive resistance exercises Warm up Exercise (for 5 min) Stretching (upper and lower extremity)~3. Progressive Resistance exercises:~1. Leg press :( dual leg press): Leg press target the~   Quadriceps or quads .but they also work your Hamstrings.~2. Leg curls (dual leg curls):~Leg curls Target the hamstrings and Calf muscles Leg Extension~The Muscles worked:~1. Rectus femoris~2. Vastus lateralis~3. Vastus medialis~4. Vastus intermedius~4. Arm lat pull (dual arm lat pull):~Back extension (lumber extension):
Study NCT06351930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I + UC group
Description: Refer to the arm description
Study NCT05460039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance mediated by tecnhology
Description: A web system and a dance mat are used to stimulate participants to perform dance activities for 8 weeks.
Study NCT04492436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thrombomodulin alfa
Description: Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
Study NCT04492436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weight based dose of reconstituted treatment administered through intravenous drip infusion on Day1 of each chemotherapy cycle
Study NCT06411275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801
Description: HTD1801 administered orally BID as two capsules
Study NCT06411275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally BID as two to four capsules
Study NCT06411275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801
Description: HTD1801 administered orally BID as four capsules
Study NCT05462431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep relaxation exercises intervention
Description: Deep relaxation exercises intervention: breathing exercise, suitable positions for rest, and relaxation exercise instructions.
Study NCT05132244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)
Description: Standard anti-hyperglycemic treatment given as directed by an endocrinologist to maintain blood glucose level within 4-10 mmol/L based on data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Participants will have access to their glucose data from the CGM.
Study NCT05132244 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard anti-hyperglycemic treatment given only if blood glucose level is greater than 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a continuous glucose monitor (CGM) but will not have access to their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
Study NCT06133283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity endurance exercise
Description: High intensity interval exercise on a recumbent stepper for 30 minutes, 3 days per week.
Study NCT06133283 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stretching exercise
Description: Stretches of face, neck, upper extremity, trunk and lower extremity muscles including whole body stretches for 30 minutes, 3 days per week.
Study NCT06133283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR)-based gaming
Description: VR games will involve games that challenge balance such as reaching different targets during activities such as sit to stand, dodging obstacles etc. Participants will play approximately 6 games for 30 minutes, 3 days a week.
Study NCT06133283 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual reality (VR)-based gaming
Description: VR games will involve games that challenge balance such as reaching different targets during activities such as sit to stand, dodging obstacles etc. Participants will play approximately 6 games for 30 minutes, 3 days a week.
Study NCT05509478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8 mg once daily (QD) oral dosing.
Study NCT05509478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitors
Description: Regular dose intravenously every 3 weeks
Study NCT06121414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laserpuncture
Description: laserpuncture use continous wave,dose 2 Joule, 785nm, 50mw